ANN ARBOR, Mich., May 03, 2007 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. 3rd Quarter Fiscal Year 2007 Investor Conference Call When: Tuesday, May 8, 2007 @ 9:00 am (EDT) Where:

FDA-Approved Phase IIb Trial Underway in U.S. to Treat Critical Limb Ischemia

ANN ARBOR, Mich., March 9, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM), a company developing cell-based therapeutics for regenerative medicine, today announced that Gerald D. Brennan, Jr., Vice President, Administrative & Financial Operations and

-- Additional Positive Patient Treatment Results Presented at the American Academy of Orthopaedic Surgeons Meeting --

ANN ARBOR, Mich., Feb 07, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM), a company developing cell-based therapeutics for regenerative medicine, today reported financial results for the second fiscal quarter ended December 31, 2006.

ANN ARBOR, Mich., Feb 02, 2007 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. 2nd Quarter Fiscal Year 2007 Investor Conference Call When: Wednesday, February 7, 2007 @ 9:00 am (EST) Where:

- Up to 150,000 People in U.S. Currently Suffer from this Severe Chronic Heart Disease

- Pivotal Bone Regeneration Trial Underway in Spain -

-- Appointment Supports New Initiatives --

Aastrom Biosciences to Present at RBC Capital Markets Healthcare Conference Ann Arbor, Michigan, December 7, 2006 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM), a clinical development stage company focused on the use of autologous cells for regenerative medicine, today announced that George W.